March 28, 2018 / 8:35 PM / 22 days ago

BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience

March 28 (Reuters) - pSivida Corp:

* PSIVIDA CORP ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS INC

* PSIVIDA CORP - SWK HOLDINGS WILL PROVIDE UP TO $20 MILLION IN DEBT FINANCING

* PSIVIDA CORP - DEAL FOR APPROXIMATELY $60.5 MILLION

* PSIVIDA CORP - PSIVIDA CORP. WILL REBRAND AND CHANGE ITS NAME TO EYEPOINT PHARMACEUTICALS INC.

* PSIVIDA CORP - ENTERED INTO A FINANCIAL AGREEMENT WITH EW HEALTHCARE PARTNERS

* PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE EQUITY INVESTMENTS IN PSIVIDA

* PSIVIDA CORP - WILL USE FUNDS TO FINANCE ICON ACQUISITION AND PREPARE FOR COMMERCIAL LAUNCHES OF DEXYCU

* PSIVIDA CORP - IF APPROVED, PSIVIDA EXPECTS TO LAUNCH DURASERT IN U.S. IN FIRST HALF OF 2019

* PSIVIDA CORP - PSIVIDA PLANS TO LAUNCH DEXYCU IN U.S. IN FIRST HALF OF 2019

* PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE AN EQUITY INVESTMENT IN PSIVIDA FOR UP TO ABOUT $60.5 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below